Company intelligence / Profile preview
HAYA Therapeutics
Lausanne / Épalinges, Vaud, Switzerlandhayatx.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
No human clinical data yet; preclinical data supports targeting lncRNAs for tissue- and cell-selective reprogramming of disease states. Lead candidate HTX-001 has shown promise in reverting myocardial fibrosis in preclinical models
- Therapeutic areas
- OncologyCardiovascularMetabolic DisordersRare Diseases
- Modalities
- Antisense oligonucleotides (ASOs)RNA therapeuticsGenomic medicines
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
Eli Lilly & Company – collaboration on discovery of novel regulatory genome targets for obesity/metabolic conditions using HAYA's RNA platform
Beyond the preview
Go deeper on HAYA Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HAYA Therapeutics.